Article

Biological Activities of Lichen-Derived Monoaromatic Compounds

Thanh-Hung Do 1, Thuc-Huy Duong 2,* , Huy Truong Nguyen 3, Thi-Hien Nguyen 2, Jirapast Sichaem 4, Chuong Hoang Nguyen 5, Huu-Hung Nguyen 6,* and Nguyen Phuoc Long 7,*

Abstract: Lichen-derived monoaromatic compounds are bioactive compounds, associated with various pharmacological properties: antioxidant, antifungal, antiviral, cytotoxicity, and enzyme inhibition. However, little is known about data regarding alpha-glucosidase inhibition and antimicrobial activity. Very few compounds were reported to have these activities. In this paper, a series of monoaromatic compounds from a lichen source were isolated and structurally elucidated. They are

1. Introduction

Lichens have produced hundreds of bioactive compounds with a range of skeletal forms [1–3]. They are associated with various pharmacological properties, being a blocker of UV radiation, antioxidant [4], antifungal [5], an inhibitor of cancer cells [6], antiviral, antimicrobial, and enzyme inhibitor [7,8]. Monocyclic aromatic compounds from lichen sources are believed to be bioactive sources. They showed potent cytotoxicity against

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
cancer cell lines [9,10], alpha-glucosidase inhibitory [7,11], anti-inflammatory [6], anti-leishmanial [12], antifungal [13], and antimicrobial activities [6,14].

Lichen-derived monoaromatic compounds were divided into two sub-classes, orcinol, and β-orscinol, depending on the presence of a substituent at C-3. However, little is known about the antimicrobial and alpha-glucosidase inhibition of monoaromatic compounds and derivatives. As a few examples, orcinol, methyl orsellinate, ethyl orsellinate, and methyl β-orsellinate showed antimicrobial activities on various microorganisms with MIC values in the range of 30–500 μg/mL [6,14]. Regarding alpha-glucosidase inhibition, methyl hematommate [11] and cristiferide A [7] showed the potent activity while methyl orsellinate and methyl β-orsellinate are weak inhibitors [15,16]. Synthetic derivatives of monoaromatic compounds were produced mainly through esterification and etherification [15,16] but their alpha-glucosidase inhibition has not been studied.

In this study, seven natural monoaromatic compounds 1–7 were isolated from the lichen Parmotrema cristiferum (Figure 1). In addition, four synthetic compounds 8a, 9a, 10a, and 10b were prepared from the corresponding starting materials 8–10 (Figure 2). Their structures were elucidated by spectroscopic data analysis and comparison with literature data. Compounds were evaluated for alpha-glucosidase inhibition and antimicrobial activity against antibiotic-resistant, pathogenic bacteria E. faecium, S. aureus, and A. baumannii.

**Figure 1.** Chemical structures of 1–10, 8a, 9a, 10a, and 10b.

**Figure 2.** Pathway to preparation of 8a, 9a, 10a, and 10b.
2. Results and Discussion

2.1. Phytochemical Identification of 1–7

From the lichen Parmotrema cristiferum, the EtOAc extract was prepared using maceration. While evaporating the solvent, the solid appeared and was collected. In this paper, compounds 1–7 were isolated from the solid part using multiple chromatographic methods. They were identified as 3,5-dihydroxybenzoic acid (1), 3,5-dihydroxybenzoate methyl (2), 3,5-dihydroxy-4-methylbenzoic acid (3), 3,5-dihydroxy-4-methoxylbenzoic acid (4), 3-hydroxycorcinol (5), atranol (6), and methyl hematommate (7). Their structures were elucidated by spectroscopic data analysis and comparison with literature data. Compounds 1–5 were reported from the Parmotrema genus for the first time. Methyl β-orsellinate (8) and methyl orsellinate (9) were isolated from the lichen P. cristiferum in the previous report [7]. Likewise, D-montagnetol (10) was available from the lichen Roccella montagnei [17].

2.2. Aromatic Bromination to Produce Compounds 8a, 9a, 10a, and 10b

Brominated substitution using sodium bromide and hydroperoxide was conducted on 8, 9, and 10 to provide products 8a, 9a, 10a, and 10b. This reaction was selected based on enhancing alpha-glucosidase inhibition of brominated derivatives from the previous reports. Particularly, the bromination of flavonoids, kamatakenin, and ayanin increased dramatically their alpha-glucosidase inhibition [18]. Further, brominated lichen metabolites showed more potent activity than their mother depsidones [19]. In contrast, esterification and etherification might decrease the activity [15,16]. Synthetic products were identified using HRESIMS, 1D-, and 2D-NMR (Figure 3).

Figure 3. Key HMBC correlations of 10a and 10b.

2.3. Alpha-Glucosidase Inhibitory Activity of Compounds 1–10, 8a, 9a, 10a, and 10b

The in vitro alpha-glucosidase inhibitory activity of natural and synthetic compounds was evaluated (Table 1). Compounds 1–5, 7, 8a, 9a, 10a, and 10b displayed potent alpha-glucosidase inhibitory activity with IC₅₀ values in the range of 24.0–171.1 µg/mL, compared with the 317 µg/mL of the acarbose positive control. Compounds 6 and 8–10 are inactive. Compounds 1–4 showed more potent activity than others, indicating the important role of 3,5-dihydroxy-1-carboxylbenzenoid ring in alpha-glucosidase inhibition. The 2,4-dihydroxy-1-carboxylbenzyl moiety of compounds 8–10 might decrease the activity. The results were similar to those reported by Lopes and co-workers (2008) [16]. Compound 7 was stronger than 6, 8, and 9, proposing that the 3-CHO group exerted a significant effect on the activity. This was consistent with the data reported by Devi and co-workers (2021) [11].
Table 1. Alpha-glucosidase inhibitory activity of compounds 1–10, 8a, 9a, 10a, and 10b.

| Compound | IC₅₀ (µg/mL) |
|----------|--------------|
| 1        | 112.3 ± 0.7  |
| 2        | 157.9 ± 2.1  |
| 3        | 24.0 ± 0.8   |
| 4        | 171.1 ± 2.9  |
| 5        | 97.3 ± 1.3   |
| 6        | >300         |
| 7        | 61.8 ± 0.4   |
| 8        | >300         |
| 9        | >300         |
| 10       | >300         |
| 8a       | 166.7 ± 2.8  |
| 9a       | 156.2 ± 2.9  |
| 10a      | 133.9 ± 4.5  |
| 10b      | 129.5 ± 2.0  |
| Acarbose | 317.0 ± 3.1  |

As regards synthetic compounds, compounds 8a, 9a, 10a, and 10b showed improved activity than their mother compounds 8, 9, and 10, indicating that the presence of the bromine atoms significantly increased the inhibition.

2.4. Antimicrobial Activity of Compounds 1–10, 8a, 9a, 10a, and 10b

Compounds 1–10, 8a, 9a, 10a, and 10b were evaluated the antimicrobial activity against antibiotic-resistant, pathogenic bacteria Enterococcus faecium, Staphylococcus aureus, and Acinetobacter baumannii (Table 2). Compounds 1–7, 10, and 10b are inactive against all tested strains. Compound 8 (methyl β-orsellinate) inhibited three selected strains with the inhibition zones of 18, 16, and 13 mm at the concentration of 50 µg/mL. Ingolfsdottir et al. (1985) reported that 8 could inhibit various microorganisms S. aureus, Bacillus subtilis, Pseudomonas aeruginosa, Candida albicans, Escherichia coli, and Aspergillus niger with MIC values in the range from 80–160 µg/mL [20]. This compound is stronger than methyl orsellinate (9). Interestingly, the synthetic products 8a and 9a obtained from 8 and 9 only showed the activity against S. aureus. Compound 9a showed more potent activity than both 8 and 9, indicating its selection against S. aureus. Its MIC value was 4 µg/mL compared to the positive control, kanamycin (MIC value of 4 µg/mL).

Table 2. Inhibition zones of antimicrobial activity of compounds 1–10, 8a, 9a, 10a, and 10b (at the concentration of 50 µg/mL).

| Compound | Inhibition Zone (mm) 50 µg/mL |
|----------|-----------------------------|
|          | Staphylococcus aureus | Acinetobacter baumannii | Enterococcus faecium |
| 1        | -                          | -                         | -                     |
| 2        | -                          | -                         | -                     |
| 3        | -                          | -                         | -                     |
| 4        | -                          | -                         | -                     |
| 5        | -                          | -                         | -                     |
| 6        | -                          | -                         | -                     |
| 7        | -                          | -                         | -                     |
| 8        | 18                         | 16                        | 13                    |
| 9        | 13                         | -                         | -                     |
| 10       | -                          | -                         | -                     |
| 8a       | 12                         | -                         | -                     |
| 9a       | 29                         | -                         | -                     |
| 10a      | -                          | -                         | 13                    |
| 10b      | -                          | -                         | -                     |
| Apramycin| 21                         | 20                        | 21                    |
2.5. Molecular Docking Studies

The pose views showed that 9a was strongly positioned in the 1t2p binding site by three h-bonds with Thr 180, Val 168, and Asn 114 and two halogen bonds with Asn 114 and Pro 163 (Figure 4), in which, the contribution to the binding site mechanism of residues such as Val 168, Thr 180, and Pro 163 has been demonstrated in the literature [21,22]. The free energy of this ligand was outstanding at $-6.7$ kcal/mol.

![Figure 4. 2D interaction diagram of ligand 9a-1t2p.](image)

For 4j5t protein, compound 3 exhibited the lowest binding energy at $-5.3$ kcal/mol, followed by 7 and 5 at $-4.8$ and $-4.3$ kcal/mol respectively. The 3–4j5t complex was supported by four h-bonds with Trp 710, Gly 566, Asn 453, and Asp 392 (Figure 5). Similarly, Trp 710, Gly 566, and Asp 392 are key residues in the hydrolysis reaction at the active site of alpha-Glucosidase I. These residues appeared also in the binding mode of compounds 5 and 7.

![Figure 5. 2D interaction diagram of ligand 3–4j5t (A), 5–4j5t (B), 7–4j5t (C).](image)

Generally, the estimated binding energies of the four ligands were consistent with the number of key interactions observed. However, with the central nucleus containing only one benzene nucleus and surrounded by polar functional groups (hydroxyl, ester, carboxylic acid), these four ligands lack the active support of hydrophobic interactions, which may explain the low affinity of those ligands to the target protein. The free energies and major residues of those complexes are presented in Table 3.
Table 3. The free energy of the complexes.

| Compound          | Docking (kcal/mol) | Binding Energy Based IC₅₀ Values (kcal/mol) | No of H-Bond Residues | No of Hydrophobic Interactions Residues |
|-------------------|--------------------|--------------------------------------------|-----------------------|----------------------------------------|
| 3-4j5t            | −4.2               | −5.3                                       | 4                     | Asn453, Gly566, Trp710, Asp392          | 2                     | Trp391 |
| 5-4j5t            | −4.0               | −4.3                                       | 4                     | Leu563, Asp568, Trp710                 | 2                     | Trp391, Arg428 |
| 7-4j5t            | −5.7               | −4.8                                       | 5                     | Asp392, Trp391, Gly566, Trp710, Glu771 | 3                     | Asp392, Glu771 |
| Acarbose-4j5t     | −6.65              | −5.16                                      | 12                    | Trp391, Asp392, Arg428, Glu429, Asp568, Leu563, Gly566, Glu771 | 1                     | Asp568 |
| 9a-1t2p           | −4.9               | −6.7                                       | 5                     | Asn114, Thr180, Val168                 | 6                     | Gln172, Leu169, Ile199, Val168 |
| Apramycin-1t2p    | −5.89              | −5.50                                      | 5                     | Asn 114, Ser116, Arg197, Thr180        | 1                     | Gln105 |

3. Materials and Methods

3.1. Source of the Lichen Material P. cristiferum

The thallus of lichen P. cristiferum was collected in Duc Trong district, Lam Dong province, Vietnam, in March 2020. The scientific name of the lichen was determined by Dr. Thi-Phi-Giao Vo, Faculty of Biology, Ho Chi Minh University of Science, National University—Ho Chi Minh City. A voucher specimen (UE-L006) was stored in the herbarium of the Department of Organic Chemistry, Ho Chi Minh University of Education.

3.2. Isolation of Compounds 1–7 from P. cristiferum

The clean, air-dried, and ground material (1.1 kg) was macerated in EtOAc at room temperature (10 L × 5 times, each time for 12 h) and the filtrated solution was evaporated under reduced pressure to produce the crude EtOAc extract (330 g). While the solvent was evaporated, the solid (T, 8.1 g) appeared and was separated by the Büchner funnel. This solid was dissolved in methanol, giving the solid and solution parts. The methanolic solution was applied to Sephadex LH-20 gel chromatography (Sigma Aldrich Co, St. Louis, MO, USA), and eluted with methanol to afford five fractions (T1-T5). The fraction T5 (2.1 g) was subjected to silica gel column chromatography (CC) using a mobile phase of n-hexane-EtOAc (stepwise, 5:1, 3:1, 1:1, v/v) to give 5 fractions (T1.1–T1.5). Fraction T1.1 (125 mg) was rechromatographed by silica gel CC with n-hexane-EtOAc: AcOH (5:1:0.02, v/v/v), afford compounds 6 (3 mg) and 7 (12 mg). Fraction T1.5 was applied to preparative thin-layer chromatography (TLC), eluted with CHCl₃-EtOAc-acetone-acetic acid (2:2:1:0.01, v/v/v/v) to provide compounds 1 (3.6 mg), 2 (7.1 mg), 3 (12.3 mg), 4 (5.2 mg), and 5 (1.4 mg).

3.3. General Procedure to Synthesize Compounds 8a and 9a

In 2.0 mL of mixture of acetic acid and DMSO (3:1, v/v), methyl β-orsellinate (8, 10.0 mg, 0.051 mmol), and sodium bromide (15.76 mg, 0.153 mmol) were dissolved at 80 °C under stirring. Then, 0.5 mL of 30% hydrogen peroxide (4.847 mmol) was added to the reaction flask. The reaction was conducted for 30 min and was periodically monitored every 5 min by TLC. After the reaction mixture was neutralized with saturated sodium hydrogen carbonate, it was further extracted with ethyl acetate-water (1:1, v/v) to gain an organic layer. The organic layer was washed thoroughly with brine three times, then dried and
applied to silica gel column chromatography (CC), eluted with n-hexane-EtOAc-acetone (10:1:2, v/v/v) to obtain 8a (13.3 mg, 95%).

A similar procedure was applied for methyl orsellinate (9, 10.0 mg, 0.055 mmol) to obtain product 9a (16.9 mg, 91%).

3.4. General Procedure to Synthesize Compounds 10a and 10b

In 5.0 mL of mixture of acetic acid, D-montagnetol (10, 50.0 mg, 0.184 mmol) and sodium bromide (56.9 mg, 0.552 mmol) were dissolved at room temperature. Then, 1.8 mL of 30% hydrogen peroxide (17.487 mmol) was added to the reaction mixture. The reaction was conducted for 30 min. The resulting solution was neutralized with saturated sodium hydrogen carbonate, then extracted with ethyl acetate-water (1:1, v/v) to gain an organic layer. This layer was subsequently washed with brine three times, then dried and applied to silica gel CC, eluted with n-hexane-EtOAc-acetone-water (2:2:2:0.01, v/v/v/v) to obtain 10a (24.5 mg, 38%) and 10b (41.6 mg, 53%).

3.5. Alpha-Glucosidase Inhibition Assay

Saccharomyces cerevisiae α-glucosidase (E.C. 3.2.1.20), acarbose, and 4-nitrophenyl β-D-glucopyranoside (pNPG) were obtained from Sigma Aldrich Co (Saint Louis, MO, USA). The alpha-glucosidase (0.2 U/mL) and substrate (5.0 mM pNPG) were dissolved in 100 mM pH 6.9 sodium phosphate buffer [19]. The inhibitor (50 µL) was preincubated with alpha-glucosidase at 37 °C for 20 min, and the substrate (40 µL) was subsequently added to the reaction mixture. The enzymatic reaction was conducted at 37 °C for 20 min and ended by adding 0.2 M Na₂CO₃ (130 µL). Enzymatic activity was quantitatively measured at an absorbance of 405 nm (CLARIOstar plus, BMG LABTECH, Ortenberg, Germany). All samples were analyzed in triplicate at five different concentrations around the IC₅₀ values, and the mean values were retained. The following equation was used to calculate the inhibition percentage (%): Inhibition (%) = [1 − (A_sample/A_control)] × 100.

3.6. Antimicrobial Activity Assay

The agar well diffusion method was utilized to investigate the antibacterial activity of the isolated compounds on antibiotic-resistant, pathogenic bacteria E. faecium, S. aureus, and A. baumannii. Three bacterial pathogens were cultured in nutrient broth at 37 °C for 18 h. The cultures were diluted with sterile 0.9% NaCl to obtain bacterial solutions of 1.5 × 10⁸ CFU/mL. This solution with a volume of 100 µL was spread on a Mueller-Hinton agar plate. Holes with a diameter of 8 mm were punched aseptically to create wells on the surface of the Mueller–Hinton agar. The compounds were dissolved in DMSO. The amount of 50 µg of each compound solution was inserted into the wells. The plates were incubated at 37 °C for 16–18 h and the antibacterial activity of each compound was recorded by measuring the diameters of the inhibition zones surrounding the wells. The determination of the minimum inhibitory concentration of 9a against Staphylococcus aureus was performed by the agar dilution method [23]. Compound 9a was dissolved in DMSO to the final concentration of 1 mg/mL and then diluted with Mueller–Hinton agar (MHA) to the concentration range of 0, 1, 2, 4, 8, 16, 32, 64 µg/mL as the final concentrations in MHA plates. S. aureus was cultured in nutrient broth at 37 °C overnight with shaking. The bacterial culture was diluted with sterile 0.9% NaCl to the concentration of 10⁷ CFU/mL. 1 µL of the diluted bacterial solution (10⁴ CFU) was placed on the surface of the MHA plates and the plates were incubated at 37 °C for 16–18 h. The MIC value was recorded as the lowest concentration of 9a that inhibited the growth of S. aureus. Kanamycin was chosen as the positive control in this experiment, while DMSO was regarded as a control.

3.7. Molecular Docking Studies

The PDB structures of proteins (4j5t and 1t2p) were downloaded from the Protein Data Bank, while the 3D structures of ligands were modeled via the website chemicalize.com. After the conversion from PDB files into a PDBQT format by AutodockTools, the docking
study was designated on AutoDock4.2 using Lamarckian genetic algorithm with 250 runs on the maximum number of evals being 25,000,000 (long) for each ligand–protein complex. The configurations with the most repetitions were employed to extract the estimated free energy as a scoring function for predicting the binding affinities to the macromolecular targets.

3.8. Structure Elucidation of the Compounds

Gravity column chromatography was performed on silica gel 60 (0.040–0.063 mm, Merck, Darmstadt, Germany). TLC for checking chromatographic patterns of fractions and isolated compounds was carried out on silica gel 60 F_{254} (Merck, Darmstadt, Germany) and spots were visualized by spraying with 10% H_2SO_4 solution followed by heating. Specific rotations were obtained on a Jasco P-1010 polarimeter (Oklahoma City, OK, USA). The HR-ESI-MS were recorded on a MicrOTOF-Q mass spectrometer (Bruker, Billerica, MA, USA). The NMR spectra were measured on a Bruker Avance 500 MHz spectrometer (Bruker, Billerica, MA, USA).

3.8.1. 3,5-Dihydroxybenzoic acid (1)

White amorphous powder. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 7.03 (d, J = 2.0 Hz, 2H, H-2,6), 6.58 (t, J = 2.0 Hz, 1H, H-4). ¹³C NMR (125 MHz, Acetone-d₆) δ_C 167.6 (C-7), 159.4 (C-3,5), 133.4 (C-1), 108.9 (C-2,6), 107.8 (C-4).

3.8.2. 3,5-Dihydroxybenzoate methyl (2)

White amorphous powder. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 7.00 (d, J = 2.0 Hz, 2H, H-2,6), 6.59 (t, J = 2.0 Hz, 1H, H-4), 3.83 (s, 3H, 7-OMe). ¹³C NMR (125 MHz, Acetone-d₆) δ_C 167.0 (C-7), 159.5 (C-3,5), 133.1 (C-1), 108.6 (C-2,6), 108.0 (C-4), 52.2 (7-OMe).

3.8.3. 3,5-Dihydroxy-4-methylbenzoic acid (3)

White amorphous powder. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 7.11 (s, 2H, H-2,6), 2.13 (s, 3H, 4-Me). ¹³C NMR (125 MHz, Acetone-d₆) δ_C 167.7 (C-7), 157.0 (C-3,5), 129.4 (C-1), 108.5 (C-2,6), 108.4 (C-4), 8.9 (4-Me) (see Figures S1 and S2).

3.8.4. 3,5-Dihydroxy-4-methoxylbenzoic acid (4)

White amorphous powder. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 7.10 (s, 2H, H-2,6), 3.78 (s, 3H, 4-OMe).

3.8.5. 3-Hydroxyorcinol (5)

Colorless oil. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 6.17 (s, 2H, H-2,6), 2.17 (s, 3H, 4-Me).

3.8.6. Atranol (6)

White amorphous powder. ¹H NMR (500 MHZ, CDCl₃) δ_H 10.34 (s, 1H, 3-CHO), 6.29 (s, 1H, H-5), 2.53 (s, 3H, 6-Me).

3.8.7. Methyl hematommate (7)

White amorphous powder. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 12.87 (s, 1H, 2-OH), 12.41 (s, 1H, 4-OH), 10.26 (s, 1H, 4-CHO), 6.25 (s, 2H, H-2,4), 3.96 (s, 3H, 7-OMe), 2.23 (s, 3H, 1-Me).

3.8.8. Methyl 5-bromo-β-orsellinate (8a)

Isolated yield 95%; White amorphous powder. ¹H NMR (500 MHZ, Acetone-d₆) δ_H 11.49 (s, 1H, 2-OH), 8.27 (s, 1H, 2-OH), 3.95 (s, 3H, 7-OMe), 2.61 (s, 3H, 6-Me), 2.13 (s, 3H, 3-Me). ¹³C NMR (125 MHZ, Acetone-d₆) δ_C 172.4 (C-7), 161.4 (C-2), 156.7 (C-4), 138.4 (C-6), 111.2 (C-3), 107.7 (C-1), 107.3 (C-5), 52.7 (7-OMe), 23.2 (6-Me), 9.3 (3-Me).
3.8.9. Methyl 3,5-dibromo-orsellinate (9a)

Isolated yield 91%; White amorphous powder. $^1$H NMR (500 MHZ, Acetone-$d_6$) $\delta_H$
11.66 (s, 1H, 2-OH), 3.99 (s, 3H, 7-OME), 2.62 (s, 3H, 6-Me). $^{13}$C NMR (125 MHZ, Acetone-$d_6$) $\delta_C$
171.6 (C-7), 159.3 (C-2), 155.9 (C-4), 140.7 (C-6), 109.5 (C-1), 106.6 (C-5), 97.6 (C-3), 53.3
(7-OME), 23.2 (6-Me). (see Figures S3 and S4).

3.8.10. 3-Bromo-D-montagnetol (10a)

Isolated yield 38%; White amorphous powder. $^1$H NMR (DMSO-$d_6$) $\delta_H$ 10.45 (brs,
1H, 2-OH), 10.02 (s, 1H, 2-OH), 6.42 (s, H-5), 4.38 ($dd$, $J = 11.0, 2.5$ Hz, H-1′a), 4.13 ($dd$, $J$
= 11.0, 6.5 Hz, H-1′b), 3.66 (m, 1H, H-2′), 3.56 (m, 1H, H-3′), 3.39 (m, 2H, H-4′), 2.28 (s,
3H, 6-Me). $^{13}$C NMR (125 MHZ, DMSO-$d_6$) $\delta_C$ 167.8 (C-7), 155.9 (C-2), 155.4 (C-4), 136.8
(C-5), 114.0 (C-1), 102.7 (C-3), 100.9 (C-5), 72.4 (C-2′), 69.3 (C-3′), 67.0 (C-1′), 63.0 (C-4′), 20.7
(6-Me). HRESI-MS m/z 348.9929 [M $-$ H]$^-$ (Calcd for C$_{12}$H$_{13}$BrO$_7$: 348.9923). [\(\alpha\)]$_D$ 25$^\circ$ +86 (c
0.1, MeOH).

3.8.11. 3,5-Dibromo-D-montagnetol (10b)

Isolated yield 53.0%; White amorphous powder. $^1$H NMR (DMSO-$d_6$) $\delta_H$ 10.25 (brs,
1H, 2-OH), 4.42 ($dd$, $J = 11.0, 2.5$ Hz, H-1′a), 4.23 ($dd$, $J = 11.0, 6.5$ Hz, H-1′b), 3.69 (m,
1H, H-2′), 3.57 (m, 1H, H-3′), 3.39 (m, 2H, H-4′), 2.38 (s, 3H, 6-Me). $^{13}$C NMR (125 MHZ, DMSO-$d_6$) $\delta_C$
167.4 (C-7), 153.4 (C-2), 153.2 (C-4), 136.4 (C-5), 114.2 (C-1), 105.8 (C-5), 99.0 (C-3), 72.4 (C-2′),
69.0 (C-3′), 67.5 (C-1′), 63.0 (C-4′), 213.6 (6-Me). HRESI-MS m/z 426.9041 [M $-$ H]$^-$ (Calcd for C$_{12}$H$_{13}$Br$_2$O$_7$: 426.9028). [\(\alpha\)]$_D$ 25$^\circ$ +154 (c 0.1, MeOH).

4. Conclusions

Seven monoaromatic compounds—3,5-dihydroxybenzoic acid (1), 3,5-dihydroxybenzoate methyl (2),
3,5-dihydroxy-4-methoxybenzoic acid (3), 3,5-dihydroxy-4-methoxylbenzoic acid (4), 3-hydroxyocircinol (5),
atranol (6), and methyl hematommate (7)—were isolated and structurally elucidated from the lichen Parmotrema cristiferum. Four synthetic compounds—methyl 5-bromo-β-orsellinate (8a), methyl 3,5-dibromo-orsellinate (9a), 3-bromo-D-montagnetol (10a),
3,5-dibromo-D-montagnetol (10b)—were synthesized using electrophilic bromination from the starting materials, methyl β-orsellinate (8), methyl orsellinate (9), and D-montagnetol (10). All compounds were evaluated for their alpha-glucosidase inhibition. Compounds 3, 5, and 7 showed strong alpha-glucosidase inhibition with IC$_{50}$ values of 24.0, 97.3, and 61.8, respectively. Other compounds showed weak or inactive. Molecular docking studies were performed, providing consistent data between in vitro and in silico studies of 3, 5, and 7, thus implying those compounds as potential candidates for further investigation. In addition, compounds were also evaluated for the antimicrobial activity against antibiotic-resistant, pathogenic bacteria Enterococcus faecium, Staphylococcus aureus, and Acinetobacter baumannii. Only the synthetic compound 9a exhibited significant activity against Staphylococcus aureus with an MIC value of 4 µg/mL. The docking study of 9a provided the molecular understanding of antimicrobial activity.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/molecules27092871/s1, Figure S1: The $^1$H NMR spectrum of 3, Figure S2: The $^{13}$C NMR spectrum of 3, Figure S3: The $^1$H NMR spectrum of 9a, Figure S4: The $^{13}$C NMR spectrum of 9a.

Author Contributions: Conceptualization, T.-H.D. (Thuc-Huy Duong); methodology, N.P.L., T.-H.D. (Thuc-Huy Duong), H.T.N.; software, H.T.N., T.-H.N., J.S.; formal analysis, T.-H.D. (Thanh-Hung Do), T.-H.D. (Thuc-Huy Duong), C.H.N.; investigation, T.-H.D. (Thanh-Hung Do), T.-H.D. (Thuc-Huy Duong); resources, H.-H.N., T.-H.D. (Thuc-Huy Duong); data curation, T.-H.D. (Thuc-Huy Duong), J.S.; writing—original draft preparation, T.-H.D. (Thuc-Huy Duong), H.T.N., N.P.L.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by Ho Chi Minh University of Education (CS2021.19.27). The study was supported by Van Lang University.
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in Supplementary Material.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. Duong, T.-H.; Hang, T.-X.-H.; Pogam, P.L.; Tran, T.-N.; Mac, D.-H.; Dinh, M.-H.; Sichaem, J. α-Glucosidase Inhibitory Depsidones from the Lichen Parmotrema tsaovense. Planta Med. 2020, 86, 776–781. [CrossRef] [PubMed]

2. Duong, T.-H.; Nguyen, V.-K.; Sichaem, J.; Tran, T.-N.; Do, T.-H.; Pham, N.-K.-T.; Nguyen, T.-A.-T.; Nguyen, T.-H.-T.; Mai, D.-T.; Nguyen, N.-H.; et al. Reticulatin, a Novel C43-Spiroterpenoid from the Lichen Parmotrema reticulatum Growing in Vietnam. Nat. Prod. Res. 2021, 1–8. [CrossRef] [PubMed]

3. Devi, A.P.; Duong, T.-H.; Ferron, S.; Beniddir, M.A.; Dinh, M.-H.; Nguyen, V.-K.; Pham, N.-K.-T.; Mac, D.-H.; Boustie, J.; Chavasiri, W.; et al. Salazinic Acid-Derived Depsidones and Diphenylethers with α-Glucosidase Inhibitory Activity from the Lichen Parmotrema dilatatum. Planta Med. 2020, 86, 1216–1224. [CrossRef] [PubMed]

4. Müller, K. Pharmacologically Relevant Metabolites from Lichens. Appl. Microbiol. Biotechnol. 2001, 56, 9–16. [CrossRef] [PubMed]

5. Millot, M.; Girardot, M.; Dutreix, L.; Mambu, L.; Imbert, C. Antifungal and Anti-Biofilm Activities of Actetone Lichen Extracts against Candida albicans. Molecules 2017, 22, 651. [CrossRef] [PubMed]

6. Boustie, J.; Tomasi, S.; Grube, M. Bioactive Lichen Metabolites: Alpine Habitats as an Untapped Source. Phytochem. Rev. 2011, 10, 287–307. [CrossRef]

7. Pham, N.-K.-T.; Nguyen, H.T.; Dao, T.-B.-N.; Vu-Huynh, K.L.; Nguyen, T.-Q.-T.; Huynh, B.-L.-C.; Le, T.-D.; Nguyen, N.-H.; Nguyen, N.-H.; Duong, T.-H. Two New Phenolic Compounds from the Lichen Parmotrema cristiferum Growing in Vietnam. Nat. Prod. Res. 2021, 1–7. [CrossRef]

8. Boustie, J.; Grube, M. Lichens—A Promising Source of Bioactive Secondary Metabolites. Plant Genet. Resour. 2005, 3, 273–287. [CrossRef]

9. Gomes, A.T.; Honda, N.K.; Roese, F.M.; Muzzi, R.M.; Sauer, L. Cytotoxic Activity of Orsellinates. Z. Für Nat. C 2006, 61, 653–657. [CrossRef]

10. Bogo, D.; Matos, M.d.F.C.; Honda, N.K.; Pontes, E.C.; Oguma, P.M.; Santos, E.C.d.S.; de Carvalho, J.E.; Nomizo, A. In Vitro Antitumour Activity of Orsellinates. Z. Für Nat. C 2010, 65, 43–48. [CrossRef]

11. Devi, A.P.; Duong, T.H.; Phan, H.-V.-T.; Nguyen, V.-K.; Chavasiri, W. Chemical Constituents of the Hexane Fraction of the Lichen Parmotrema dilatatum and Their α-Glucosidase Inhibition Activity. Chem. Nat. Compd. 2021, 57, 528–530. [CrossRef]

12. Schmeda-Hirschmann, G.; Tapia, A.; Limb, B.; Pertino, M.; Sortino, M.; Zacchino, S.; de Arias, A.R.; Feresin, G.E. A New Antifungal and Antiprotozoal Depside from the Andean Lichen Protousnea poeppigii: A New Antifungal Depside from Protousnea poeppigii. Phytother. Res. 2008, 22, 349–355. [CrossRef] [PubMed]

13. Min, T.-J.; Bae, K.-G. Structure and antibiotic activities of phenolic compounds from Unbilicaria vella. J. Korean J. Chem Soc. 1996, 40, 623–629.

14. Ingólfsdóttir, K.; Gudmundsdóttir, G.F.; Ögmundsdóttir, H.M.; Paulus, K.; Haraldsdóttir, S.; Kristinsson, H.; Bauer, R. Effects of Tenuiorin and Methyl Orsellinate from the Lichen Pelligeran leucophleba on 5-/15-Lipoxygenases and Proliferation of Malignant Cell Lines in Vitro. Phytomedicine 2002, 9, 654–658. [CrossRef]

15. Rama Krishna, B.; Ramakrishna, S.; Rajendra, S.; Madhusudana, K.; Mallavadhani, U.V. Synthesis of Some Novel Orsellinates and Lecanoric Acid Related Depsides as α-Glucosidase Inhibitors. J. Asian Nat. Prod. Res. 2019, 21, 101301027. [CrossRef]

16. Lopes, T.I.B.; Coelho, R.G.; Yoshida, N.C.; Honda, N.K. Radical-Scavenging Activity of Orsellinates. Chem. Pharm. Bull. 2008, 56, 1551–1554. [CrossRef]

17. Duong, T.H.; Huynh, B.L.C.; Chavasiri, W.; Chollet-Krugler, M.; Nguyen, V.K.; Nguyen, T.H.T.; Hansen, P.E.; Le Pogam, P.; Thüs, H.; Boustie, J.; et al. New Erythritol Derivatives from the Fertile Form of Roccella montagnei. Phytochemistry 2017, 137, 156–164. [CrossRef]

18. Dao, T.-B.-N.; Nguyen, T.-M.-T.; Nguyen, V.-Q.; Tran, T.-M.-D.; Tran, N.-M.-A.; Nguyen, C.H.; Nguyen, T.-H.-T.; Nguyen, H.-H.; Sichaem, J.; Tran, C.-L.; et al. Flavones from Combretum quadrangulare Growing in Vietnam and Their Alpha-Glucosidase Inhibitory Activity. Molecules 2021, 26, 2531. [CrossRef]

19. Pham, N.-K.-T.; Tran, N.-M.-A.; Truong Nguyen, H.; Pham, D.-D.; Nguyen, T.-Q.-T.; Nguyen, T.-H.-A.; Nguyen, H.-T.; Do, T.-H.; Nguyen, N.-H.; Duong, T.-H. Design, Modification, and Bio-Evaluation of Salazinic Acid Derivatives. Arab. J. Chem. 2022, 15, 103535. [CrossRef]

20. Ingólfsdóttir, K.; Bloomfield, S.F.; Hylands, P.J. In Vitro Evaluation of the Antimicrobial Activity of Lichen Metabolites as Potential Preservatives. Antimicrob. Agents Chemother. 1985, 28, 289–292. [CrossRef]

21. Zong, Y.; Rice, T.W.; Ton-That, H.; Schneewind, O.; Narayana, S.V.L. Crystal Structures of Staphylococcus aureus Sortase A and Its Substrate Complex. J. Biol. Chem. 2004, 279, 31383–31389. [CrossRef] [PubMed]
22. Barker, M.K.; Rose, D.R. Specificity of Processing α-Glucosidase I Is Guided by the Substrate Conformation. *J. Biol. Chem.* **2013**, *288*, 13563–13574. [CrossRef] [PubMed]

23. Balouiri, M.; Sadiki, M.; Ibnsouda, S.K. Methods for in Vitro Evaluating Antimicrobial Activity: A Review. *J. Pharm. Anal.* **2016**, *6*, 71–79. [CrossRef] [PubMed]